NBTX:NASDAQNanobiotix S.A. Analysis

Nanobiotix (NBTX) is trading at $49.48, comfortably above its 20‑day SMA ($40.25) and 50‑day SMA ($35.38), with a bullish MACD histogram (+1.32) and RSI at 62, indicating strong short‑term momentum. However, the stock is markedly overvalued – forward PE of 340x, price‑to‑sales of 73x, and a negative book value per share, while operating margins are deeply negative and cash burn remains high. Volatility is extreme (109% 30‑day) and beta is elevated (≈2.4), reflecting a high‑risk profile despite the bullish technical setup.
Recent material news highlights a protocol amendment to the global Phase 3 head‑and‑neck cancer study and presentation of Phase 2 data for NBTXR3 in inoperable lung cancer, suggesting potential catalyst events that could swing sentiment. Analyst consensus is a “strong buy” with median target $36, well below the current price, underscoring the disconnect between market enthusiasm and fundamental valuation.